295 related articles for article (PubMed ID: 8827950)
1. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent.
Ernsberger P; Koletsky RJ; Collins LA; Bedol D
Cardiovasc Drugs Ther; 1996 Jun; 10 Suppl 1():275-82. PubMed ID: 8827950
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB).
Ernsberger P; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Friedman JE
J Pharmacol Exp Ther; 1999 Jan; 288(1):139-47. PubMed ID: 9862764
[TBL] [Abstract][Full Text] [Related]
3. Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
Friedman JE; Ishizuka T; Liu S; Farrell CJ; Koletsky RJ; Bedol D; Ernsberger P
Blood Press Suppl; 1998; 3():32-9. PubMed ID: 10321453
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.
Ernsberger P; Koletsky RJ; Friedman JE
Ann N Y Acad Sci; 1999 Nov; 892():272-88. PubMed ID: 10842668
[TBL] [Abstract][Full Text] [Related]
5. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
Ernsberger P; Friedman JE; Koletsky RJ
J Hypertens Suppl; 1997 Jan; 15(1):S9-23. PubMed ID: 9050981
[TBL] [Abstract][Full Text] [Related]
6. Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study.
Mikulášková B; Holubová M; Pražienková V; Zemenová J; Hrubá L; Haluzík M; Železná B; Kuneš J; Maletínská L
Nutr Diabetes; 2018 Jan; 8(1):5. PubMed ID: 29339795
[TBL] [Abstract][Full Text] [Related]
7. Influence of different dietary salts on the cardiovascular and renal effects of moxonidine in spontaneously hypertensive rats.
Mervaala EM; Malmberg L; Teräväinen TL; Lähteenmäki T; Karjala K; Paakkari I; Pörsti I; Mest HJ; Vapaatalo H; Karppanen H
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jul; 356(1):107-14. PubMed ID: 9228197
[TBL] [Abstract][Full Text] [Related]
8. Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat.
Friedman JE; Ishizuka T; Liu S; Farrell CJ; Bedol D; Koletsky RJ; Kaung HL; Ernsberger P
Am J Physiol; 1997 Nov; 273(5):E1014-23. PubMed ID: 9374689
[TBL] [Abstract][Full Text] [Related]
9. Cardiac effects of moxonidine in spontaneously hypertensive obese rats.
Mukaddam-Daher S; Menaouar A; El-Ayoubi R; Gutkowska J; Jankowski M; Velliquette RA; Ernsberger P
Ann N Y Acad Sci; 2003 Dec; 1009():244-50. PubMed ID: 15028594
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P
J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894
[TBL] [Abstract][Full Text] [Related]
11. Marked insulin resistance in obese spontaneously hypertensive rat adipocytes is ameliorated by in vivo but not in vitro treatment with moxonidine.
Sun Z; Ernsberger P
J Pharmacol Exp Ther; 2007 Feb; 320(2):845-52. PubMed ID: 17095615
[TBL] [Abstract][Full Text] [Related]
12. Contrasting metabolic effects of antihypertensive agents.
Velliquette RA; Ernsberger P
J Pharmacol Exp Ther; 2003 Dec; 307(3):1104-11. PubMed ID: 14557373
[TBL] [Abstract][Full Text] [Related]
13. Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.
Wyss JM; Mozaffari MS; Roysommuti S
J Hypertens; 1995 Sep; 13(9):1037-42. PubMed ID: 8586822
[TBL] [Abstract][Full Text] [Related]
14. Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats.
Carlson SH; Shelton J; White CR; Wyss JM
Hypertension; 2000 Jan; 35(1 Pt 2):403-8. PubMed ID: 10642332
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
16. Acceleration of renal disease in obese SHR by exacerbation of hypertension.
Koletsky RJ; Boccia J; Ernsberger P
Clin Exp Pharmacol Physiol Suppl; 1995 Dec; 22(1):S254-6. PubMed ID: 9072379
[TBL] [Abstract][Full Text] [Related]
17. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Ernsberger P
J Pharmacol Exp Ther; 2003 Aug; 306(2):646-57. PubMed ID: 12756274
[TBL] [Abstract][Full Text] [Related]
18. Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome.
Selejan SR; Linz D; Tatu AM; Hohl M; Speer T; Ewen S; Mahfoud F; Kindermann I; Zamyatkin O; Kazakov A; Laufs U; Böhm M
J Mol Cell Cardiol; 2018 Sep; 122():34-46. PubMed ID: 30096408
[TBL] [Abstract][Full Text] [Related]
19. The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones.
Bing C; King P; Pickavance L; Brown M; Ziegler D; Kaan E; Williams G
Br J Pharmacol; 1999 May; 127(1):35-42. PubMed ID: 10369453
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the sympathetic nervous system in antihypertensive effect of cicletanine in salt-loaded young spontaneously hypertensive rats.
Ando K; Ono A; Sato Y; Asano S; Fujita T
Am J Hypertens; 1994 Jun; 7(6):550-4. PubMed ID: 7917154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
